Holen Sie sich die Stockscreener-App
438.95
3.30%
14.01
Handel nachbörslich:
439.52
0.57
+0.13%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$424.94
Offen:
$425.58
24-Stunden-Volumen:
1.63M
Relative Volume:
0.62
Marktkapitalisierung:
$237.31B
Einnahmen:
$37.30B
Nettoeinkommen (Verlust:
$7.80B
KGV:
30.53
EPS:
14.3793
Netto-Cashflow:
$8.60B
1W Leistung:
+6.32%
1M Leistung:
+13.82%
6M Leistung:
+25.36%
1J Leistung:
+44.71%
1-Tages-Spanne:
$425.11
$439.05
1-Wochen-Bereich:
$415.20
$441.76
52-Wochen-Spanne:
$288.00
$447.03
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
438.95 | 237.31B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,286.79 | 1.15T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.42 | 625.18B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
289.08 | 510.84B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.30 | 365.88B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.63 | 292.01B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2026-08-05 | Bestätigt | BMO Capital Markets | Outperform |
| 2026-08-05 | Bestätigt | BofA Securities | Underperform |
| 2026-08-05 | Bestätigt | Canaccord Genuity | Hold |
| 2026-08-05 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2026-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2026-08-05 | Bestätigt | RBC Capital Mkts | Outperform |
| 2026-08-05 | Bestätigt | Robert W. Baird | Underperform |
| 2026-08-05 | Bestätigt | Truist | Hold |
| 2026-08-05 | Bestätigt | Wells Fargo | Equal Weight |
| 2026-05-05 | Herabstufung | Erste Group | Buy → Hold |
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Hold |
| 2026-03-10 | Eingeleitet | Jefferies | Hold |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-20 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 - PR Newswire
Amgen (AMGN) and AstraZeneca Report Positive Phase 3 Trial Resul - GuruFocus
From Discovery to Delivery: 5 Ways Amgen Is Putting Sustainability into Practice - www.marketscreener.com
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study - Benzinga
Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis - Seeking Alpha
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Reuters
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS - Amgen
Amgen Inc. $AMGN Stock Bought by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
Dona’s Story: Strengthening Her Bones After a Postmenopausal Osteoporosis Diagnosis - Amgen
10,773 Amgen Inc. $AMGN Shares Sold by Novem Group - MarketBeat
Greg Jennings LLC Buys New Position in Amgen Inc. $AMGN - MarketBeat
Mattel appoints Amgen's Peter Griffith as CFO, succeeding Paul Ruh - Reuters
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Amgen Has the Drugs and the Dividend. Now It Needs the Growth - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Inc. $AMGN Stock Sold by First Bank & Trust - MarketBeat
2,560 Amgen Inc. $AMGN Shares Sold by Generali Investments Management Co LLC - MarketBeat
Beat the Market the Zacks Way: Valero Energy, Hagerty, Palantir in Focus - Zacks Investment Research
Amgen Inc. $AMGN Position Lifted by IFP Advisors Inc - MarketBeat
Amgen Inc. $AMGN Stock Sold by TD Waterhouse Canada Inc. - MarketBeat
Amgen Inc. $AMGN Stock: Frank Rimerman Advisors LLC Raises Holdings - MarketBeat
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
Here's Why Amgen (AMGN) is a Strong Momentum Stock - Zacks Investment Research
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? - The Motley Fool
Amgen (AMGN) Laps the Stock Market: Here's Why - Zacks Investment Research
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Stock Market News for Oct 8, 2026 - Zacks Investment Research
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
Can Amgen (NASDAQ:AMGN) Win With Direct-to-Patient Access Programs? - Kalkine Media
3,524 Amgen Inc. $AMGN Shares Sold by Colton Groome Financial Advisors LLC - MarketBeat
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance UK
Amgen Inc. $AMGN Shares Purchased by MassMutual Private Wealth & Trust FSB - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Ferguson Wellman Capital Management Inc. - MarketBeat
2,546 Amgen Inc. $AMGN Shares Sold by Argent Capital Management LLC - MarketBeat
AMGEN INC. R (AMG.MU) Q2 FY2026 earnings call transcript - Yahoo Finance
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com - Investing.com India
Is AMGN Overvalued? DCF Says Worth $189 - GuruFocus
Amgen Inc Stock Futures,Dec-202 (SAMGN=F) Interactive Stock Chart - Yahoo! Finance Canada
Amgen Inc. $AMGN Shares Sold by CX Institutional - MarketBeat
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock - benzinga.com
Amgen Inc. (AMGN34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amgen Inc Investor Call At IASLC 2019 World Conference on Lung Cancer Transcript - GuruFocus
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amgen Inc-Aktie (AMGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
| Khosla Rachna | Officer |
Aug 13 '26 |
Proposed Sale |
412.76 |
1,252 |
516,775 |
0 |
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | Officer |
Aug 11 '26 |
Proposed Sale |
414.21 |
2,000 |
828,420 |
0 |
| Derek Miller | Officer |
Aug 06 '26 |
Proposed Sale |
404.85 |
3,890 |
1,574,866 |
0 |
| Grygiel Nancy A. | Officer |
Aug 06 '26 |
Proposed Sale |
447.17 |
2,670 |
1,193,940 |
0 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Option Exercise |
177.41 |
2,970 |
526,906 |
9,310 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Option Exercise |
169.56 |
3,890 |
659,574 |
14,531 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Sale |
402.54 |
3,890 |
1,565,898 |
12,462 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Sale |
402.16 |
2,970 |
1,194,415 |
7,340 |
2.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):